Bioqube Ventures

Bioqube Ventures is a specialist life sciences venture capital firm focused on early-stage investments in Europe, particularly in therapeutic assets and disruptive healthcare technologies. Founded in 2016 by Debora Dumont and Nico Vandervelpen, the firm launched its independent fund, Bioqube Factory Fund I, in 2020. This fund, which has secured over €60 million in its initial closing, aims to support the development of breakthrough therapies by leveraging Bioqube's unique dual investment model. This model includes both traditional venture investments and a "Create" strategy, which focuses on de-risking projects before establishing new ventures. The fund's strategy is deeply rooted in supporting high-potential scientific innovations, transforming them into commercially viable biotechnologies. Bioqube has strong partnerships with prominent investors like the European Investment Fund, Johnson & Johnson Innovation, and Genmab, further bolstering its ability to drive significant advancements in the life sciences sector. The Bioqube team is composed of experienced fund managers, sector experts, and serial entrepreneurs, bringing a hands-on approach to guiding portfolio companies through their growth stages. The firm has a significant presence in Europe, with a focus on regions such as the Benelux, France, and Germany, aiming to build a new generation of leading biotech companies.